Last updated: February 20, 2026
ZEGERID (omeprazole and sodium bicarbonate) is an over-the-counter (OTC) antacid used to treat gastroesophageal reflux disease (GERD), ulcers, and indigestion. The drug combines omeprazole, a proton pump inhibitor, with sodium bicarbonate, which neutralizes stomach acid.
Current Manufacturing and Supply Chain
Primary Manufacturer
- AstraZeneca: Originally developed and marketed ZEGERID until 2018, AstraZeneca's rights to OTC formulations were acquired by other entities. The original formulation was produced by AstraZeneca's contract manufacturing partners.
Contract Manufacturers
- Production involves contract manufacturing organizations (CMOs) with facilities equipped for sterile, high-precision pharmaceutical manufacturing.
- Major CMOs for proton pump inhibitors include companies such as Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, and Dr. Reddy’s Laboratories.
Licensors and Distributors
- Bausch Health (formerly Valeant Pharmaceuticals) now markets ZEGERID OTC formulations in some regions, utilizing multiple suppliers of active ingredients and excipients.
Key Ingredient Suppliers
| Ingredient |
Supplier Companies |
Notes |
| Omeprazole |
Dr. Reddy’s Laboratories, Teva, TAPI (Taiwan Pharma), others |
Bulk active pharmaceutical ingredient (API) sourced globally; large divisions dedicated to proton pump inhibitors. |
| Sodium Bicarbonate |
Local suppliers in manufacturing countries, e.g., PG Chemicals, Novus International |
Widely available, with many generic suppliers worldwide. |
Supply Chain Dynamics
- API Sourcing: Omeprazole API is produced largely in India, China, and Taiwan. These regions dominate global supply due to cost efficiency and manufacturing capacity.
- Excipients: Sodium bicarbonate and other excipients are easily sourced from regional chemical suppliers.
- Formulation and Packaging: Manufacturing occurs in multiple countries, with final assembly often in North America or Europe for branded products.
Market Competition and Supply Risks
- Market Competition: Numerous generic manufacturers produce omeprazole-based formulations, reducing dependency on single suppliers.
- Supply Risks:
- Geopolitical tensions affecting supply chains, especially in China and India.
- Regulatory changes, such as new GMP requirements, which could impact production capacity.
- Raw material shortages, particularly for active ingredients in recent years due to supply chain disruptions.
Regulatory Environment Impact
- FDA and EMA Regulations: Both agencies enforce strict standards for API and finished medicinal products. Certificates of suitability (CEP) and drug master files (DMF) influence sourcing.
- Patent Expiry: The original patent for ZEGERID expired in multiple jurisdictions, allowing widespread manufacturing.
Recent Developments
- Generic Entry: Multiple generics launched in the US post-2018, diversifying suppliers.
- Supply Chain Resilience Initiatives: Manufacturers increased API inventories and diversified sourcing to mitigate risks from global disruptions, including the COVID-19 pandemic.
Overview Summary
| Aspect |
Details |
| Main API suppliers |
Dr. Reddy’s, Teva, TAPI (Taiwan Pharma) |
| Geographic focus |
India, China, Taiwan |
| Major manufacturers |
Contracted facilities globally; brands include Teva, Sun Pharma, etc. |
| Key ingredients |
Omeprazole, sodium bicarbonate |
| Regulatory influences |
FDA, EMA standards, patent landscape |
| Market dynamics |
High generic competition, supply chain diversification underway |
Conclusions
Multiple suppliers and manufacturing sources underpin ZEGERID’s global availability. Suppliers operate primarily from India, China, and Taiwan, with a competitive landscape among generics reducing proprietary dependency. Supply chain risks remain, with ongoing efforts to diversify sources and maintain manufacturing capacity.
Key Takeaways
- ZEGERID's active ingredients predominantly sourced from India, China, and Taiwan.
- Major contract manufacturers include Teva, Sun Pharma, and Dr. Reddy's.
- Increased global focus on supply chain resilience due to recent disruptions.
- Generic competition has expanded manufacturing sources since patent expiry.
- Regulatory standards influence sourcing and manufacturing strategies.
FAQs
1. Who are the main API suppliers for omeprazole used in ZEGERID?
The leading API suppliers include Dr. Reddy’s Laboratories, Teva, and Taiwan Pharma (TAPI).
2. Which regions supply the raw ingredients for ZEGERID?
India, China, and Taiwan dominate API production; excipients like sodium bicarbonate are sourced globally from chemical suppliers.
3. How has patent expiry affected ZEGERID's manufacturing?
Patent expiration around 2018 opened the market for multiple generic manufacturers, increasing supplier diversity.
4. What are the main risks to ZEGERID’s supply chain?
Risks include geopolitical tensions, raw material shortages, regulatory changes, and COVID-19 impacts.
5. Which companies currently manufacture or distribute ZEGERID?
Bausch Health markets ZEGERID in some regions, with contract manufacturing by several global CMOs, including Teva and Sun Pharma.
References
- AstraZeneca. (2021). Zegerid Capsules: Product Information. [Online] Available at: https://www.astrazeneca.com
- U.S. Food and Drug Administration (FDA). (2022). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
- Teva Pharmaceutical Industries. (2022). Global API Supply Chain Overview. [Online] Available at: https://www.tevapharm.com
- Sun Pharmaceutical Industries. (2021). Operational and Supply Chain Details. [Online] Available at: https://www.sunpharma.com
- Dr. Reddy’s Laboratories. (2023). API Production and Source. [Online] Available at: https://www.drreddys.com
